regardless of promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from managed care entities. These insurers are https://kobibchy865878.timeblog.net/77934155/copyright-s-drug-faces-is-dealing-with-pbm-hurdles-a-review-of-reimbursement-battles